ACHV on Nasdaq
ACHIEVE LIFE SCIENCES, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2019
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total operating expenses | $54.9M | $39.1M | $27.2M |
| Interest income | $1.5M | $2.4M | $825.0K |
| Interest expense [note 8] | -$819.0K | -$2.2M | -$2.9M |
| Change in fair value of contingent consideration [note 5 and note 6] | -$408.0K | -$621.0K | -$528.0K |
| Loss on extinguishment of 2023 SVB convertible term loan [note 8] | -$283.0K | ||
| Other income (expense) | -$36.0K | -$30.0K | -$9.0K |
| Total other income (expense) | $232.0K | -$758.0K | -$2.6M |
| Net Loss | -$54.6M | -$39.8M | -$29.8M |
| Net unrealized gain (loss) on securities | -$21.0K | $27.0K | |
| Total other comprehensive income (loss) | -$21.0K | $27.0K | |
| Comprehensive loss | -$54.7M | -$39.8M | -$29.8M |
| Basic net loss per common share [note 10 [i]] | -$1.25 | -$1.24 | -$1.50 |
| Diluted net loss per common share [note 10 [i]] | -$1.25 | -$1.24 | -$1.50 |
| Shares used in computation of basic net loss per common share [note 10 [i]] | 43.6M shares | 32.1M shares | 19.8M shares |
| Shares used in computation of Diluted net loss per common share [note 10 [i]] | 43.6M shares | 32.1M shares | 19.8M shares |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents [note 3 and note 6] | $20.9M | $12.8M | |
| Marketable securities [note 6] | $15.5M | $21.6M | |
| Total current assets | $39.9M | $36.5M | |
| Restricted cash and other assets [note 6 and note 7] | $52.0K | $39.0K | |
| Right-of-use assets [note 12] | $64.0K | $119.0K | |
| License agreement [note 4 and note 5] | $751.0K | $974.0K | |
| Goodwill | $1.0M | $1.0M | |
| Total assets | $41.8M | $38.6M | |
| Accrued clinical liabilities | $368.0K | $1.1M | |
| Accrued compensation | $1.9M | $3.0M | |
| Current contingent consideration [note 5 and note 6] | $1.6M | $0 | |
| Current portion of long-term obligations [note 12] | $61.0K | $55.0K | |
| Current portion of convertible debt [note 6 and note 8] | $3.7M | ||
| Total current liabilities | $9.1M | $6.7M | |
| Non-current portion of convertible debt [note 6 and note 8] | $11.2M | $9.8M | |
| Non-current contingent consideration [note 5 and note 6] | $0 | $1.1M | |
| Long-term obligations [note 12] | $5.0K | $66.0K | |
| Total liabilities | $20.3M | $17.7M | |
| Common stock, $0.001 par value, 150,000,000 shares authorized, 53,233,988 and 34,685,072 issued and outstanding at December 31, 2025 and December 31, 2024, respectively. | $121.0K | $103.0K | |
| Additional paid-in capital | $281.6M | $226.3M | |
| Accumulated deficit | -$260.2M | -$205.6M | |
| Accumulated other comprehensive income | $10.0K | $31.0K | |
| Total stockholders' equity | $21.5M | $20.9M | -$1.4M |
| Total liabilities and stockholders' equity | $41.8M | $38.6M | |
| Preferred stock, par value | $0.00 | ||
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 150.0M shares | 150.0M shares | |
| Common stock, shares issued | 53.2M shares | 34.7M shares | |
| Common stock, shares outstanding | 53.2M shares | 34.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$54.6M | -$39.8M | -$29.8M |
| Depreciation and amortization [note 4] | $228.0K | $229.0K | $228.0K |
| Stock-based compensation [note 10[c], note 10[d], note 10[e]] and note 10[f]] | $8.8M | $5.3M | $3.4M |
| Shares issued as settlement with trade vendor | $0 | $273.0K | |
| Accrued interest on SVB convertible debt [note 8] | $0 | $799.0K | $1.2M |
| Amortization of 2024 SVB convertible term loan transaction costs [note 8] | $52.0K | $23.0K | |
| Accretion of discount on modification of debt [note 8] | $365.0K | $430.0K | |
| Loss on extinguishment of 2023 SVB convertible term loan [note 8] | $283.0K | ||
| Change in fair value of contingent consideration [note 4 and note 5] | $408.0K | $621.0K | $528.0K |
| Grant receivable | $111.0K | -$6.0K | |
| Accrued clinical liabilities | -$709.0K | $797.0K | -$1.4M |
| Accrued compensation | -$1.1M | $716.0K | $633.0K |
| Lease obligation | $0 | -$1.0K | -$58.0K |
| Net cash used in operating activities | -$49.5M | -$29.8M | -$24.5M |
| Proceeds from exercise of warrants [note 10[g]] | $1.4M | $682.0K | $227.0K |
| Proceeds from employee stock purchase plan [note 10[e]] | $0 | $178.0K | |
| Taxes paid related to net share settlement of equity awards | $0 | -$114.0K | -$220.0K |
| Proceeds from June 2025 public offering exercise of overallotment option, net of issuance costs [note 10b] | $4.0M | ||
| Repayment of 2023 SVB convertible term loan [note 6 and note 8] | -$18.1M | ||
| Receipt of 2024 SVB convertible term loan less transaction costs [note 6 and note 8] | $9.8M | ||
| Receipt of 2024 SVB convertible term loan second tranche [note 6 and note 8] | $5.0M | ||
| Net cash provided by financing activities | $51.5M | $48.5M | $15.3M |
| Purchase of property and equipment | -$3.0K | -$21.0K | |
| Loss on disposal of property and equipment | -$1.0K | ||
| Realized gain on investments | $4.0K | ||
| Purchase of investments | -$24.8M | -$47.9M | |
| Maturities of investments | $30.9M | $26.3M | |
| Net cash provided by (used in) investing activities | $6.1M | -$21.6M | -$21.0K |
| Effect of exchange rate changes on cash | $3.0K | -$3.0K | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $8.2M | -$2.8M | -$9.2M |
Former names
Recent filings
- Oct 6, 20263
- Oct 6, 20264
- Oct 1, 20268-K
- Aug 21, 20264
- Aug 19, 2026144
- Aug 17, 2026SCHEDULE 13G
- Aug 14, 2026424B5
- Aug 14, 20268-K
- Aug 13, 2026SCHEDULE 13G
- Aug 11, 20268-K
- Aug 11, 202610-Q
- Jul 29, 20264
- Jul 29, 20264
- Jul 29, 20264
- Jul 29, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9